# Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

> **NCT03020628** · PHASE3 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 171 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** NBP607-QIV
- **BIOLOGICAL:** NBP607-TIV

## Key facts

- **NCT ID:** NCT03020628
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-03
- **Final completion:** 2017-06
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2017-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03020628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03020628, "Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03020628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*